Cargando…

Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports

BACKGROUND: Adverse drug reaction (ADR) is a major burden for patients and healthcare industry. Early and accurate detection of potential ADRs can help to improve drug safety and reduce financial costs. Post-market spontaneous reports of ADRs remain a cornerstone of pharmacovigilance and a series of...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ruoqi, Zhang, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918608/
https://www.ncbi.nlm.nih.gov/pubmed/31849321
http://dx.doi.org/10.1186/s12911-019-0999-1
_version_ 1783480625059069952
author Liu, Ruoqi
Zhang, Ping
author_facet Liu, Ruoqi
Zhang, Ping
author_sort Liu, Ruoqi
collection PubMed
description BACKGROUND: Adverse drug reaction (ADR) is a major burden for patients and healthcare industry. Early and accurate detection of potential ADRs can help to improve drug safety and reduce financial costs. Post-market spontaneous reports of ADRs remain a cornerstone of pharmacovigilance and a series of drug safety signal detection methods play an important role in providing drug safety insights. However, existing methods require sufficient case reports to generate signals, limiting their usages for newly approved drugs with few (or even no) reports. METHODS: In this study, we propose a label propagation framework to enhance drug safety signals by combining drug chemical structures with FDA Adverse Event Reporting System (FAERS). First, we compute original drug safety signals via common signal detection algorithms. Then, we construct a drug similarity network based on chemical structures. Finally, we generate enhanced drug safety signals by propagating original signals on the drug similarity network. Our proposed framework enriches post-market safety reports with pre-clinical drug similarity network, effectively alleviating issues of insufficient cases for newly approved drugs. RESULTS: We apply the label propagation framework to four popular signal detection algorithms (PRR, ROR, MGPS, BCPNN) and find that our proposed framework generates more accurate drug safety signals than the corresponding baselines. In addition, our framework identifies potential ADRs for newly approved drugs, thus paving the way for early detection of ADRs. CONCLUSIONS: The proposed label propagation framework combines pre-clinical drug structures with post-market safety reports, generates enhanced drug safety signals, and can potentially help to accurately detect ADRs ahead of time. AVAILABILITY: The source code for this paper is available at: https://github.com/ruoqi-liu/LP-SDA.
format Online
Article
Text
id pubmed-6918608
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69186082019-12-20 Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports Liu, Ruoqi Zhang, Ping BMC Med Inform Decis Mak Research Article BACKGROUND: Adverse drug reaction (ADR) is a major burden for patients and healthcare industry. Early and accurate detection of potential ADRs can help to improve drug safety and reduce financial costs. Post-market spontaneous reports of ADRs remain a cornerstone of pharmacovigilance and a series of drug safety signal detection methods play an important role in providing drug safety insights. However, existing methods require sufficient case reports to generate signals, limiting their usages for newly approved drugs with few (or even no) reports. METHODS: In this study, we propose a label propagation framework to enhance drug safety signals by combining drug chemical structures with FDA Adverse Event Reporting System (FAERS). First, we compute original drug safety signals via common signal detection algorithms. Then, we construct a drug similarity network based on chemical structures. Finally, we generate enhanced drug safety signals by propagating original signals on the drug similarity network. Our proposed framework enriches post-market safety reports with pre-clinical drug similarity network, effectively alleviating issues of insufficient cases for newly approved drugs. RESULTS: We apply the label propagation framework to four popular signal detection algorithms (PRR, ROR, MGPS, BCPNN) and find that our proposed framework generates more accurate drug safety signals than the corresponding baselines. In addition, our framework identifies potential ADRs for newly approved drugs, thus paving the way for early detection of ADRs. CONCLUSIONS: The proposed label propagation framework combines pre-clinical drug structures with post-market safety reports, generates enhanced drug safety signals, and can potentially help to accurately detect ADRs ahead of time. AVAILABILITY: The source code for this paper is available at: https://github.com/ruoqi-liu/LP-SDA. BioMed Central 2019-12-18 /pmc/articles/PMC6918608/ /pubmed/31849321 http://dx.doi.org/10.1186/s12911-019-0999-1 Text en © Liu and Zhang. 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Liu, Ruoqi
Zhang, Ping
Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports
title Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports
title_full Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports
title_fullStr Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports
title_full_unstemmed Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports
title_short Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports
title_sort towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918608/
https://www.ncbi.nlm.nih.gov/pubmed/31849321
http://dx.doi.org/10.1186/s12911-019-0999-1
work_keys_str_mv AT liuruoqi towardsearlydetectionofadversedrugreactionscombiningpreclinicaldrugstructuresandpostmarketsafetyreports
AT zhangping towardsearlydetectionofadversedrugreactionscombiningpreclinicaldrugstructuresandpostmarketsafetyreports